uniQure's gene therapy for Huntington's disease nears FDA decision with strong 3-year data, stock rated Speculative Buy.

uniQure's gene therapy AMT-130 for Huntington's disease is under FDA accelerated review with a decision expected by November 1. The therapy showed strong three-year data meeting FDA endpoints, slowing disease progression significantly, despite market concerns over less favorable four-year data. The stock is rated Speculative Buy with a $47 price target, implying a 115% upside. This gene therapy could become a breakthrough treatment for a disease with no current therapies, making it a notable investment opportunity.

uniQure's market capitalization stands at $1.45 billion as of Oct 15, 2026, 21:41 WIB, with a trading volume of 3,323,243 shares on Pluang. The stock price is currently USD 21.78, showing a 3.91% increase in the last day. Pluang data indicates strong buying interest with 100% of order activity on the buy side at this time.